Sandoz's Zessly (infliximab) Receives EU Approval for Gastroenterological- Rheumatological And Dermatological Diseases
Shots:
- The approval is based on non-inferiority and P-III REFLECTIONS B537-02 study results assessing Zessly vs reference drug and demonstrated meeting 1EPs with safety- efficacy and quality
- Zessly is 3rd EC approval in 12 mos. and 6th biosimilar approval for Sandoz
- Zessly (infliximab) is a mAb- blocks the action of tumor necrosis factor (TNF)-alpha in patients with autoimmune disorders
Ref: Sandoz | Image: Princeton Forrestal Center
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com